Takeda and Arbor Pharmaceuticals Form Licensing Agreement - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Takeda and Arbor Pharmaceuticals Form Licensing Agreement

Takeda and Arbor Pharmaceuticals Ireland, a wholly owned subsidiary of Arbor Pharmaceuticals, have entered into a license, development, and commercialization agreement. Under which Arbor will receieve with exclusive rights to market and sell the antihypertensive drugs, Edarbi (azilsartan medoxomil) and Edarbyclor (azilsartan medoxomil and chlorthalidone) in the United States, effective Sept. 12, 2013.

Under the agreement, Arbor will have exclusive rights to promote and sell Edarbi and Edarbyclor in the US. In return, Takeda will receive an upfront payment along with a series of future milestone and royalty payments based upon sales of the Edarbi family of products.

Source: Takeda


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns

Click here